ACES Stock Overview
A biotech company, focuses on orphan oncology treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 20.55 |
| 52 Week High | SEK 20.55 |
| 52 Week Low | SEK 20.45 |
| Beta | 0.74 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACES | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.0% | 1.2% |
| 1Y | n/a | -22.1% | 5.9% |
Return vs Industry: Insufficient data to determine how ACES performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ACES performed against the UK Market.
Price Volatility
| ACES volatility | |
|---|---|
| ACES Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ACES has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACES's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 21 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACES fundamental statistics | |
|---|---|
| Market cap | SEK 672.69m |
| Earnings (TTM) | -SEK 115.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs ACES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACES income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 115.48m |
| Earnings | -SEK 115.48m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 04, 2022
| Earnings per share (EPS) | -3.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACES perform over the long term?
See historical performance and comparison